Progress in new drugs targeting reverse cholesterol transport

Chinese Pharmacological Bulletin

Volumn 22, Issue 8, 2006, Pages 904-907

  Luo, Qing Feng ^a   Sun, Lan ^a   Du, Guan Hua ^b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Artherosclerosis; High density lipoprotein; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; DRUG TARGETING; DYSLIPIDEMIA;

EID: 33750094673     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rader D J. High-density lipoproteine as an emerging therapeutic target for atherosclerosis[J]. JAMA, 2003, 290(17):2322-4.
2. Moore R E, Navab M, Millar J S, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation[J]. Circ Res, 2005, 97(8):763-71.
3. Chiesa G, Monteggia E, Marchesi M, et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks[J]. Circ Res, 2002, 90(9): 974-80.
4. Nissen S E, Tsunoda T, Tuzcu E M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial[J]. JAMA, 2003, 290(17):2292-300.
5. Navab M, Anantharamaiah G M, Reddy S T, et al. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal[J]. Curr Opin Lipidol, 2004, 15(6):645-9.
6. Navab M, Anantharamaiah G M, Reddy S T, et al. Apolipoprotein A-I mimetic peptides[J]. Arterioscler Thromb Vasc Biol, 2005, 25(7):1325-31.
7. Burgess J W, Neville T A, Rouillard P, et al. Phosphatidylinositol increases HDL-C levels in humans[J]. J Lipid Res, 2005, 46 (2):350-5.
8. Miao B, Zondlo S, Gibbs S, et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator[J]. J Lipid Res, 2004, 45(8):1410-7.
9. Beyer TP, Schmidt RJ, Foxworthy P, et al. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo [J]. J Pharmacol Exp Ther, 2004, 309(3):861-8.
10. Srivastava N. ATP binding cassette transporter A1-key roles in cellular lipid transport and atherosclerosis[J]. Mol Cell Biochem, 2002, 237(1-2):155-64.
11. Chinetti G, Fruchart J C, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall[J]. Z Kardiol, 2001, 90(Suppl 3):125-32.
12. Oliver WR Jr, Shenk J L, Snaith M R, et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport[J]. Proc Natl Acad Sci USA, 2001, 98(9): 5306-11.
13. Singh J P, Kauffman R, Bensch W, et al. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo4,5-dihydro-1H-1,2,4-triazol-3-yl] propyl}phenoxy) propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression[J]. Mol Pharmacol, 2005, 68(3): 763-8.
14. Reifel-Miller A, Otto K, Hawkins E, et al. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia[J]. Mol Endocrinol, 2005, 19(6):1593-605.
15. Skrumsager B K, Nielsen K K, Muller M, et al. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes[J]. J Clin Pharmacol, 2003, 43(11): 1244-56.
16. Saad M F, Greco S, Osei K, et al. Ragaglitazar dose-ranging study group. Hagaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm [J]. Diabetes Care, 2004, 27(6):1324-9.
17. de Grooth G J, Kuivenhoven J A, Stalenhoef A F, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study [J]. Circulation, 2002, 105(18):2159-65.
18. Kuivenhoven J A, de Grooth G J, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia[J]. Am. J Cardiol, 2005, 95(9):1085-8.
19. Clark R W, Sutfin T A, Ruggeri R B, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib[J]. Arterioscler Thromb Vasc Biol, 2004, 24(3):490-7.
20. Brousseau M E, Diffenderfer M R, Millar J S, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion[J]. Arterioscler Thromb Vasc Biol, 2005, 25(5):1057-64.
21. Nakagawa-Toyama Y, Hirano K, Tsujii K, et al. Human scavenger receptor class B type I is expressed with cell-specific fashion in both initial and terminal site of reverse cholesterol transport[J]. Atherosclerosis, 2005, 183(1):75-83.
22. Imachi H, Murao K, Cao W, et al. Expression of human scavenger receptor B1 on and in human platelets[J]. Arterioscler Thromb Vasc Biol, 2003, 23(5):898-904.
23. Pilon A, Martin G, Bultel-Brienne S, et al. Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line[J]. Biochim Biophys Acta, 2003, 1631(3):218-28.
24. Svensson P A, Englund M C, Snackestrand M S, et al. Regulation and splicing of scavenger receptor class B type I in human macrophages and atherosclerotic plaques[J]. BMC Cardiorasc Disord, 2005, 25;5:25